Selective Internal Radiation Therapy With 90Y Resin Micropheres for Refractory Colorectal Cancer Liver Metastases

Study Overview
=================
Brief Summary
-----------------
Observational, feasibility study investigating biological aspects in patients with liver metastasis from colorectal cancer undergoing treatment with SIRT, by translational analysis of biological samples.

Detailed Description
-----------------
In this study, the investigators seek to investigate biological aspects in patients with colorectal cancer liver metastasis undergoing treatment with Selective Internal Radiation Therapy, by translational analysis of biological samples. SIRT will be conducted as per standard procedure at Aarhus University Hospital. Translational blood samples will be drawn pre-treatment and during follow up. The total cell free DNA level will be quantified in all samples. The samples will be analysed for tumour specific mutations such as the KRAS, BRAF and NRAS oncogenes. The investigators expect to include up to 30 patients. This is a purely observational translational study. Results will be analysed in relation to outcome data. The study is conducted in collaboration with: Department of Gastroenterology and Hepatology, Aarhus University Hospital Department of Radiology, Aarhus University Hospital Department of Nuclear Medicine, Aarhus University Hospital

Official Title
-----------------
Selective Internal Radiation Therapy With 90Y Resin Micropheres for Refractory Colorectal Cancer Liver Metastases - SIRT - A Translational Feasibility Study

Conditions
-----------------
Liver Metastasis Colon Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of metastatic colorectal adenocarcinoma with liver dominant disease Diagnosis of liver metastasis may be made by histo- or cyto-pathology, or by clinical and imaging criteria. The Liver metastasis are not eligible for resection, RFA or SBRT All patients must be off all chemotherapeutic regimens for 14 days prior to SIRT treatment All patients must be off vascular endothelial growth factor inhibitors for 6 weeks prior to SIRT treatment Progressive disease, severe intolerance during or following all standard lines of chemo-therapy Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 Age 18 years or older Able to understand written information Consent to samples for translational research Exclusion Criteria: Pretherapeutic work-up procedure with Tc-99m macroaggregated albumin (MAA) scintigraphy showing extrahepatic foci in GI-tract Evidence of any detectable Tc-99m macroaggregated albumin deposition in the stomach or duodenum, after application of established angiographic techniques to stop such deposition Previous radiation therapy to the lungs and/or to the upper abdomen overlapping with dose to the liver at interventionist´s decision Lung shunt greater than 20% or > 30 Gray radiation absorbed dose to the lungs, at estimated by Tc-99m-MAA Pregnancy Symptomatic lung disease precluding SIRT at interventionist´s decision Active uncontrolled infection Any pre-treatment laboratory findings within 30 days of treatment demonstrating: alanine aminotransferase level greater than 5 times upper normal limit and/or serum bilirubin greater than 2 mg/dl (>34 umol/l) Current or previously evidence of ascites on CT-scan or physical examination Tumour volume greater than 50% of liver volume Conditions precluding translational samples

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Feasibility and translational analysis | Investigating potential prognostic and predictive markers for efficacy by molecular characteristics and mutational analysis | When 5 patients are included, the blood samples will be analysed for explorative analysis (expected after the first year). In all we expect to include 30 patients if positive results. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Response Rate | According to RECIST 1.1 | 6 months | 
| Progression Free Survival |  | 3 years | 
| Overall Survival |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Liver metastasis Colon Cancer, Circulating Tumour DNA, Selective Internal Radiation Therapy